Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio fundamental para evaluar el beneficio clínico, el rendimiento y la seguridad de un sistema de implante coclear totalmente implantable (TICI) en adultos (ELEVATE)

29 de septiembre de 2026 actualizado por: Cochlear

Estudio Pivotal, Precomercialización, Prospectivo, Intervencionista, Multicéntrico para Evaluar el Beneficio Clínico, el Rendimiento y la Seguridad del Implante TI1132 en una Población Adulta con Hipoacusia Neurosensorial

This pivotal study examines the clinical efficacy and safety of an investigational totally implantable cochlear implant (TICI) system. The system includes a microphone placed under the skin to detect speech and sound from the environment, providing the option to hear without any visible external parts. This study will involve adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve (the nerve that carries sound signals from the ear to the brain). Participants will complete hearing tests and questionnaires to evaluate how well the system works and how it affects their daily life.

Descripción general del estudio

Estado

Activo, no reclutando

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

56

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Colorado
      • Englewood, Colorado, Estados Unidos, 80113
        • Rocky Mountain Ear Center
    • Florida
      • Miami, Florida, Estados Unidos, 33136
        • University of Miami School of Medicine
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • University of Iowa
    • Michigan
      • Novi, Michigan, Estados Unidos, 48374
        • Michigan Ear Institute
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55902
        • Mayo Foundation Rochester
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64111
        • Midwest Ear Institute
      • St Louis, Missouri, Estados Unidos, 63108
        • Washington University School of Medicine
    • New York
      • New York, New York, Estados Unidos, 10017
        • NYU Langone Health
    • Ohio
      • Beachwood, Ohio, Estados Unidos, 44122
        • University Hospitals Cleveland Medical Centre
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73120
        • Hearts for Hearing Foundation
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84132
        • University of Utah Hospitals and Clinics

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Individuals aged 18 years and older at time of consent.
  • Clinically established sensorineural hearing loss (SNHL) defined by a four frequency (500, 1000, 2000, 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥70 dB HL in the ear to be implanted.
  • Compromised functional hearing in the aided condition defined as ≤40% correct on a word recognition test in the ear to be implanted.
  • Clinically established SNHL defined by a four-frequency (500, 1000, 2000 & 4000 Hz) pure-tone average unaided threshold (PTA4) of ≥30 dB HL in the contralateral ear.
  • Candidate is a fluent speaker in the language used to assess speech perception performance as determined by the investigator.
  • Direct access to a compatible Smart Phone.
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • Prior cochlear implantation, in either ear, or medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted.
  • Candidates with single-sided deafness as determined by the investigator.
  • Intra-axial (within-the-brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted.
  • Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment.
  • Presence of a tympanic membrane perforation or a history of otologic surgery within 3 months prior to enrolment, in the ear to be implanted.
  • Previously reported diagnosis of auditory neuropathy, in the ear to be implanted.
  • Ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, in the ear to be implanted.
  • Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, skull fracture or CSF leaks.
  • Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the participant.
  • Severe, or poorer, sensorineural hearing loss for more than 20 years, as reported by the participant, in the ear to be implanted.
  • Medical or psychological conditions that contraindicate general anaesthesia, surgery, or participation in the clinical investigation as determined by the investigator.
  • Pre-existing skin condition that could jeopardize wound healing as judged by the investigator e.g., psoriasis, dermatitis, use of corticosteroids, uncontrolled diabetes.
  • Unrealistic expectations on the part of the participant, regarding the possible benefits, risks, and limitations inherent to the surgical procedure(s) and prosthetic devices, as determined by the Investigator.
  • Additional disabilities that may affect the participant's participation or safety during the clinical investigation.
  • Unable or unwilling to comply with all requirements of the clinical investigation, as determined by the investigator.
  • Pregnant or breastfeeding women.
  • Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as spouse, parent, child or sibling.
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of the investigation.
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by Investigator or Sponsor to not impact this investigation).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Totally Implantable Cochlear Implant System

Participants will be implanted with the TI1132 implant

Totally Implantable Cochlear Implant System

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Speech recognition performance in quiet
Periodo de tiempo: Preimplantation to 6-months post-activation

Percent correct scores in word recognition score from pre-implantation to post-implantation.

Preimplantation to 6-months post-activation
Incidence of adverse events and device deficiencies
Periodo de tiempo: Implantation to 6- and 12-months post-activation

Frequency and severity of device and procedure-related adverse events, including device deficiencies.

Implantation to 6- and 12-months post-activation

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Speech, Spatial and Qualities of Hearing questionnaire (SSQ-12)
Periodo de tiempo: Preimplantation to 6- and 12-months post-activation

Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability).

Preimplantation to 6- and 12-months post-activation
Speech recognition performance in noise
Periodo de tiempo: Preimplantation to 6- and 12-months post-activation

Percent correct sentence score from preimplantation to 6- and 12-months post-activation.

Preimplantation to 6- and 12-months post-activation
Speech recognition performance in quiet
Periodo de tiempo: Preimplantation to 12-months post-activation

Percent correct word recognition score in quiet from pre-implantation to post-implantation.

Preimplantation to 12-months post-activation
Cochlear Implant Quality of Life Profile (CIQOL-35)
Periodo de tiempo: Preimplantation to 6- and 12-months post-activation

Cochlear implant hearing related quality of life score (CIQOL-35). Scored for six health domains (communication, emotional, entertainment, environment, listening effort, and social) each scaled from 0 to 100, where a higher score indicates better health.

Preimplantation to 6- and 12-months post-activation
Health Utilities Index (HUI 2/3)
Periodo de tiempo: Preimplantation to 6- and 12-months post-activation

Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health".

Preimplantation to 6- and 12-months post-activation
Living with Cochlear Implants Questionnaire (LivCI)
Periodo de tiempo: Preimplantation to 6- and 12-months post-activation

Living with Cochlear Implants Questionnaire (LivCI) evaluates the impact of a hearing device on four domains, Participation (range 0 to 12), Psychosocial & Wellbeing (range 0 to 21), Stigma (range 0 to 15) and Management & Aesthetics (range 0 to 18), where a higher domain score indicates positive patient report.

Preimplantation to 6- and 12-months post-activation
Patient Satisfaction Survey
Periodo de tiempo: From 6 to 12 months post-activation

Device satisfaction rating score. Scores range from 1 to 5, where a higher score indicates greater patient satisfaction with the TICI system.

From 6 to 12 months post-activation

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Craig Buchman, University of Utah

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

3 de abril de 2026

Finalización primaria (Estimado)

1 de octubre de 2027

Finalización del estudio (Estimado)

1 de agosto de 2028

Fechas de registro del estudio

Enviado por primera vez

11 de diciembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

11 de diciembre de 2025

Publicado por primera vez (Actual)

17 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

1 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir